<DOC>
	<DOCNO>NCT01403259</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety SOX regimen ( S-1 plus oxaliplatin ) salvage treatment patient relapse metastatic nasopharyngeal carcinoma .</brief_summary>
	<brief_title>SOX Salvage Treatment Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>The treatment option patient platinum-resistant relapsed metastatic nasopharyngeal carcinoma limit . Previous study show S-1 oxaliplatin effective head neck cancer . Moreover , SOX ( S-1 plus oxaliplatin ) prove tolerable advanced stage gastric cancer . Therefore , aim evaluate regimen salvage set nasopharyngeal carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age range : 1875 year old Histological confirm incurable relapse metastatic nasopharyngeal carcinoma Prior exposure least one line platinumcontaining regimen ECOG performance status 01 Life expectancy 3 month Bone marrow function : ANC≧1.5×109/L , PLT≧100×109/L , Hb≧80g/L Liver function : total bilirubin , ALT AST &lt; 1.5×UNL Renal function : Cr &lt; 1.5×UNL , CCR≧50ml/min Without &gt; 1 grade neuropathy With curable treatment option With CNS involvement Prior platinum exposure neoadjuvant/adjuvant set concurrently use radiotherapy Treated &gt; 2 line palliative chemotherapy With prior exposure S1 oxaliplatin History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Significant active infection Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>S-1</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>